{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"256.60","upperLimit":"2000.00","value":"2000.00"},{"groupId":"OG001","lowerLimit":"495.80","upperLimit":"2000.00","value":"2000.00"}]}],"title":"CXCL10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.00","upperLimit":"6024.40","value":"40.60"},{"groupId":"OG001","lowerLimit":"1.00","upperLimit":"231.70","value":"24.60"}]}],"title":"Granzyme B"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.50","upperLimit":"1876.00","value":"410.25"},{"groupId":"OG001","lowerLimit":"7.50","upperLimit":"1876.00","value":"442.75"}]}],"title":"IFN-gamma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"158.40","upperLimit":"9000.00","value":"1782.65"},{"groupId":"OG001","lowerLimit":"639.20","upperLimit":"5012.20","value":"1783.05"}]}],"title":"IL-1 RA"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.90","upperLimit":"77.60","value":"5.85"},{"groupId":"OG001","lowerLimit":"0.90","upperLimit":"21.50","value":"6.70"}]}],"title":"IL-2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.60","upperLimit":"976.00","value":"86.00"},{"groupId":"OG001","lowerLimit":"3.20","upperLimit":"976.00","value":"50.70"}]}],"title":"IL-6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.30","upperLimit":"72.80","value":"32.20"},{"groupId":"OG001","lowerLimit":"13.50","upperLimit":"81.30","value":"31.80"}]}],"title":"IL-7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.60","upperLimit":"750.00","value":"41.19"},{"groupId":"OG001","lowerLimit":"10.60","upperLimit":"140.70","value":"53.20"}]}],"title":"IL-8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.70","upperLimit":"246.10","value":"16.55"},{"groupId":"OG001","lowerLimit":"3.40","upperLimit":"349.30","value":"246.10"}]}],"title":"IL-10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.70","upperLimit":"188.70","value":"40.30"},{"groupId":"OG001","lowerLimit":"27.10","upperLimit":"80.90","value":"35.60"}]}],"title":"IL-15"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.00","upperLimit":"116.57","value":"9.50"},{"groupId":"OG001","lowerLimit":"2.60","upperLimit":"62.50","value":"10.85"}]}],"title":"TNF alpha"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Peak was defined as the maximum post-baseline level of the cytokine.","dispersionType":"Full Range","groups":[{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 2 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG000","title":"Cohort 1: 2 x 10^6 Brexucabtagene Autoleucel"},{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 0.5 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG001","title":"Cohort 2: 0.5 x 10^6 Brexucabtagene Autoleucel"}],"paramType":"MEDIAN","populationDescription":"Participants in the Safety Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline up to Week 4","title":"Peak Serum Levels of C-X-C Motif Chemokine 10 (CXCL10), Granzyme B, Interferon-Gamma (IFN-γ), Interleukin-1 Receptor Antagonist (IL-1RA), Interleukin (IL)-2, IL-6, IL-7, IL-8,IL-10, IL-15, and Tumor Necrosis Factor-Alpha (TNF-α) in Blood","type":"SECONDARY","unitOfMeasure":"pg/mL"}